Insights

In a world of low-cost capital and investor pressure for earnings growth, M&A is still top of the agenda for senior pharmaceutical executives. But it is the more creative world of partnerships – through the likes of licensing, co-development, capability and risk sharing, technology collaborations and joint ventures – that has been a potent force in the industry’s successes in recent years. Partnerships can truly bring out the best in both sides of the deal, if each party is prepared to re-think how they operate and create the right balance of trust and control. In this paper, we explore what companies are spending and getting for their external investments, how they are partnering to create value, and what is required to succeed with partnerships. We conclude by contrasting partnerships with M&A as sources of sustainable business growth.

To view the contents of this post, please submit your email address and you will gain access to all posts on our web site...






Click here if you would like to receive emails from us. Read our privacy policy

To receive details of new white papers and events please enter your details below

Click here if you would like to receive emails from us. Read our privacy policy

Newsletter Signup